Journal article
Effect of a 2 1 schedule of ten-valent versus 13-valent pneumococcal conjugate vaccine on pneumococcal carriage: Results from a randomised controlled trial in Vietnam
B Temple, ML Nation, VTT Dai, J Beissbarth, K Bright, EM Dunne, J Hinds, PT Hoan, J Lai, CD Nguyen, BD Ortika, TV Phan, HNL Thuy, NT Toan, DY Uyen, C Satzke, H Smith-Vaughan, TN Huu, K Mulholland
Vaccine | Published : 2021
Abstract
Background: Pneumococcal conjugate vaccines (PCVs) generate herd protection by reducing nasopharyngeal (NP) carriage. Two PCVs, PCV10 and PCV13, have been in use for over a decade, yet there are few data comparing their impact on carriage. Here we report their effect on carriage in a 2+1 schedule, compared with each other and with unvaccinated controls. Methods: Data from four groups within a parallel, open-label randomised controlled trial in Ho Chi Minh City contribute to this article. Three groups were randomised to receive a 2+1 schedule of PCV10 (n = 250), a 2+1 schedule of PCV13 (n = 251), or two doses of PCV10 at 18 and 24 months (controls, n = 197). An additional group (n = 199) was ..
View full abstractGrants
Awarded by Bill and Melinda Gates Foundation
Funding Acknowledgements
We thank the study participants and their families, the study staff, and the laboratory staff from the Pasteur Institute of Ho Chi Minh City, the Menzies Child Health team, and the MCRI Translational Microbiology group. We acknowledge the contributions of Dang Duc Anh, Nguyen Thi Hien Anh, Dorota Borys, Jonathan Carapetis, Nguyen Thi Kieu Chinh, Nguyen Le Dang, Lam Trung Duc, Katherine Gould, Ahsan Habib, William Hausdorff, Bernard Hoet, Nguyen Huu Hung, Vu Thi Que Huong (deceased), Phan Trong Lan, Tran Thi Kim Ngan, Vo Thuy Ngoc, Peter Paradiso, Nguyen Thi Minh Phuong (deceased), Nguyen Ngo Quang, Fiona Russell, Hoang Hoa Son, and Lay Myint Yoshida. This work was supported by the National Health and Medical Research Council of Australia (grant number 566792) and the Bill & Melinda Gates Foundation (grant number OPP1116833). CS is the recipient of a NHMRC Career Development Fellowship (1087957) and a Veski Inspiring Women Fellowship. GlaxoSmithKline Biological SA donated the doses of PCV10. We also acknowledge the Victorian Government's Operational Infrastructure Support Program.